Rectal Adenocarcinoma — Trials

Rectal Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

187 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 52
Recruiting: 28
Ph III recruiting: 3
Growth YoY: —
Industry share: 2%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 39.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (32)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05627635	FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer	active not recruiting	Phase 1 / Phase 2	20	City of Hope Medical CenterOTHER	1	Sep 1, 2026	clinicaltrials
NCT04599140	SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial	active not recruiting	Phase 1 / Phase 2	51	M.D. Anderson Cancer CenterOTHER	1	Jul 20, 2026